Results 1 to 10 of about 151,365 (368)

Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals [PDF]

Nature Medicine, 2022
In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara—Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that ...
Luca M. Zaeck, Mart M. Lamers, Babs E. Verstrepen, Theo M. Bestebroer, Martin E. van Royen, Hannelore M Götz, Marc C. Shamier, Leanne P. M. van Leeuwen, Katharina S. Schmitz, Kimberley Alblas, Suzanne van Efferen, Susanne Bogers, Sandra Scherbeijn, Guus F. Rimmelzwaan, Eric C. M. Van Gorp, Marion Koopmans, Bart L. Haagmans, Corine H. GeurtsvanKessel, Rory D. de Vries   +18 more
openalex   +2 more sources

The MVA priority approximation [PDF]

ACM Transactions on Computer Systems, 1984
A Mean Value Analysis (MVA) approximation is presented for computing the average performance measures of closed-, open-, and mixed-type multiclass queuing networks containing Preemptive Resume (PR) and nonpreemptive Head-Of-Line (HOL) priority service centers.
Raymond M. Bryant, Anthony E. Krzesinski, M. Seetha Lakshmi, K. Mani Chandy   +3 more
openaire   +4 more sources

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial [PDF]

PLoS ONE, 2018
BackgroundModified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral ...
Chaplin, Paul, De Carli, Sonja, Kreusel, Christian, Lawrence, Steven J, Meyer, Thomas P, Nopora, Katrin, Overton, Edgar Turner, Rosch, Siegfried, Samy, Nathaly, Schnidt, Darja, Wagner, Eva, Weidenthaler, Heinz, Young, Philip   +12 more
core   +4 more sources

Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models

Expert Review of Vaccines, 2017
Introduction: Despite 30 years of research on HIV, a vaccine to prevent infection and limit disease progression remains elusive. The RV144 trial showed moderate, but significant protection in humans and highlighted the contribution of antibody responses ...
Lynette Siv Chea, Rama Rao Amara
doaj   +2 more sources

Poxviral promoters for improving the immunogenicity of MVA delivered vaccines

Human Vaccines & Immunotherapeutics, 2019
Modified vaccinia virus Ankara (MVA) is a replication-deficient poxvirus, attenuated in chick embryo fibroblast primary cells. It has been utilised as a viral vector to develop many vaccines against cancer and infectious diseases such as malaria, HIV ...
Naif Khalaf Alharbi
doaj   +2 more sources

The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host [PDF]

Antiviral Research, 2018
African horse sickness (AHS) is a lethal equine disease transmitted by Culicoides biting midges and caused by African horse sickness virus (AHSV). AHS is endemic to sub-Saharan Africa, but devastating outbreaks have been recorded periodically outside ...
Calvo-Pinilla, Eva, Castillo-Olivares, Javier, Gubbins, Simon, Mertens, Peter P.C., Ortego, Javier   +4 more
core   +3 more sources

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

Proceedings of the National Academy of Sciences of the United States of America, 2021
Significance The highly attenuated vaccinia virus MVA is licensed as smallpox vaccine; as a vector it is a component of the approved adenovirus-MVA–based prime-boost vaccine against Ebola virus disease.
Alina Tscherne, J. Schwarz, Cornelius Rohde, A. Kupke, Georgia Kalodimou, Leonard Limpinsel, Nisreen M. A. Okba, B. Bošnjak, I. Sandrock, Iva Odak, Sandro Halwe, Lucie Sauerhering, K. Brosinski, Nan Liangliang, E. Duell, S. Jany, Astrid Freudenstein, Jörg Schmidt, A. Werner, Michelle Gellhorn Serra, Michael Klüver, W. Guggemos, M. Seilmaier, C. Wendtner, R. Förster, B. Haagmans, S. Becker, G. Sutter, A. Volz   +28 more
semanticscholar   +2 more sources

Cross-reactive immune responses to monkeypox virus induced by MVA vaccination in mice

Virology Journal, 2023
Mpox (monkeypox) infection cases increased recently in non-Mpox outbreak areas, potentially causing an international threat. The desire to defend against a potential outbreak has led to renewed efforts to develop Mpox vaccines.
Fei-xia Gao, Cheng He, Min Liu, P. Yuan, Shihua Tian, Mei Zheng, Linya Zhang, Xu Zhou, Fangjingwei Xu, Jian Luo, Xiuling Li   +10 more
semanticscholar   +1 more source

Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine

Journal of Infectious Diseases, 2023
Background Respiratory syncytial virus (RSV) causes significant disease burden in older adults. MVA-BN-RSV is a novel poxvirus-vectored vaccine encoding internal and external RSV proteins. Methods In a phase 2a randomized double-blind, placebo-controlled
E. Jordan, Golam Kabir, S. Schultz, G. Silbernagl, D. Schmidt, Victoria A Jenkins, H. Weidenthaler, D. Stroukova, Barbara K Martin, L. de Moerlooze   +9 more
semanticscholar   +1 more source

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Vaccines, 2023
Prevention of mpox has become an important public health interest. We aimed to evaluate the safety and immunogenicity of the Modified Vaccinia Ankara (MVA) vaccine. We conducted a systematic review and meta-analysis of randomized-controlled trials (RCTs)
Lior Nave, I. Margalit, Noam Tau, I. Cohen, D. Yelin, F. Lienert, D. Yahav   +6 more
semanticscholar   +1 more source